# Perspective Therapeutics, Inc.: financial statements, quarterly

CATX · NYSE · CIK 728387 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/catx.md) · [Financials](/companies/catx/financials.md) · [Filings](/companies/catx/filings.md) · [Insiders](/companies/catx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/catx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.2](/filings/0001437749-23-032036.md) | [(4.9) d](/filings/0001437749-24-009696.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $m | [1.4](/filings/0001437749-23-032036.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | [0.7](/filings/0001437749-23-032036.md) | [(0.0) d](/filings/0001437749-24-009696.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [5.6](/filings/0000950170-24-125399.md) | [7.1 d](/filings/0000950170-25-046758.md) | [7.5](/filings/0000950170-25-069314.md) | [9.3](/filings/0000950170-25-107619.md) | [12.0](/filings/0001193125-25-274328.md) | [12.9 d](/filings/0000728387-26-000004.md) | [14.3](/filings/0001193125-26-216790.md) | [16.6](/filings/0001193125-26-342512.md) | [20.3](/filings/0001193125-25-274328.md) | [32.9 d](/filings/0000728387-26-000004.md) | [21.4](/filings/0001193125-26-216790.md) | [21.5](/filings/0001193125-26-342512.md) |
| Operating income | $m | [(9.8)](/filings/0000950170-24-125399.md) | [(11.7) d](/filings/0000950170-25-046758.md) | [(13.0)](/filings/0000950170-25-069314.md) | [(14.3)](/filings/0000950170-25-107619.md) | [(18.6)](/filings/0001193125-25-274328.md) | [(45.0) d](/filings/0000728387-26-000004.md) | [(21.8)](/filings/0001193125-26-216790.md) | [(24.0)](/filings/0001193125-26-342512.md) | [(27.9)](/filings/0001193125-25-274328.md) | [(39.8) d](/filings/0000728387-26-000004.md) | [(28.3)](/filings/0001193125-26-216790.md) | [(29.3)](/filings/0001193125-26-342512.md) |
| Interest expense | $m | [0.0](/filings/0001437749-23-032036.md) | [0.0 d](/filings/0001437749-24-009696.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001437749-23-032036.md) | [7.8 d](/filings/0000950170-25-046758.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(10.4)](/filings/0000950170-24-125399.md) | [(24.7) d](/filings/0000950170-25-046758.md) | [(12.3)](/filings/0001193125-25-274328.md) | [(11.7)](/filings/0001193125-25-274328.md) | [(15.1)](/filings/0001193125-25-274328.md) | [(40.2) d](/filings/0000728387-26-000004.md) | [(18.2)](/filings/0001193125-26-342512.md) | [(21.5)](/filings/0001193125-26-342512.md) | [(26.0)](/filings/0001193125-25-274328.md) | [(37.5) d](/filings/0000728387-26-000004.md) | [(26.2)](/filings/0001193125-26-342512.md) | [(26.8)](/filings/0001193125-26-342512.md) |
| Diluted EPS | $ per share | [(0.37)](/filings/0000950170-24-125399.md) | not reported | [(0.25)](/filings/0000950170-25-069314.md) | [(0.18)](/filings/0000950170-25-107619.md) | [(0.21)](/filings/0001193125-25-274328.md) | not reported | [(0.25)](/filings/0001193125-26-216790.md) | [(0.29)](/filings/0001193125-26-342512.md) | [(0.35)](/filings/0001193125-25-274328.md) | not reported | [(0.25)](/filings/0001193125-26-216790.md) | [(0.22)](/filings/0001193125-26-342512.md) |
| Basic EPS | $ per share | [(0.37)](/filings/0000950170-24-125399.md) | not reported | [(0.25)](/filings/0000950170-25-069314.md) | [(0.18)](/filings/0000950170-25-107619.md) | [(0.21)](/filings/0001193125-25-274328.md) | not reported | [(0.25)](/filings/0001193125-26-216790.md) | [(0.29)](/filings/0001193125-26-342512.md) | [(0.35)](/filings/0001193125-25-274328.md) | not reported | [(0.25)](/filings/0001193125-26-216790.md) | [(0.22)](/filings/0001193125-26-342512.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [18.0](/filings/0000950170-24-125399.md) | [9.2](/filings/0000950170-25-046758.md) | [142](/filings/0000950170-25-069314.md) | [252](/filings/0000950170-25-107619.md) | [226](/filings/0000950170-24-125399.md) | [61.6](/filings/0000728387-26-000004.md) | [44.4](/filings/0000950170-25-069314.md) | [28.8](/filings/0000950170-25-107619.md) | [26.8](/filings/0001193125-25-274328.md) | [30.6](/filings/0001193125-26-342512.md) | [54.0](/filings/0001193125-26-216790.md) | [48.5](/filings/0001193125-26-342512.md) |
| Current assets | $m | [21.7](/filings/0001437749-23-032036.md) | [16.8](/filings/0000950170-25-046758.md) | [188](/filings/0000950170-24-060427.md) | [294](/filings/0000950170-24-096148.md) | [270](/filings/0000950170-24-125399.md) | [231](/filings/0000728387-26-000004.md) | [216](/filings/0000950170-25-069314.md) | [196](/filings/0000950170-25-107619.md) | [179](/filings/0001193125-25-274328.md) | [148](/filings/0001193125-26-342512.md) | [275](/filings/0001193125-26-216790.md) | [242](/filings/0001193125-26-342512.md) |
| Total assets | $m | [111](/filings/0001437749-23-032036.md) | [97.9](/filings/0000950170-25-046758.md) | [278](/filings/0000950170-24-060427.md) | [386](/filings/0000950170-24-096148.md) | [391](/filings/0000950170-24-125399.md) | [341](/filings/0000728387-26-000004.md) | [329](/filings/0000950170-25-069314.md) | [311](/filings/0000950170-25-107619.md) | [295](/filings/0001193125-25-274328.md) | [267](/filings/0001193125-26-342512.md) | [411](/filings/0001193125-26-216790.md) | [392](/filings/0001193125-26-342512.md) |
| Current liabilities | $m | [8.1](/filings/0001437749-23-032036.md) | [15.7](/filings/0000950170-25-046758.md) | [14.5](/filings/0000950170-24-060427.md) | [10.6](/filings/0000950170-24-096148.md) | [28.1](/filings/0000950170-24-125399.md) | [18.2](/filings/0000728387-26-000004.md) | [12.7](/filings/0000950170-25-069314.md) | [13.0](/filings/0000950170-25-107619.md) | [20.6](/filings/0001193125-25-274328.md) | [28.7](/filings/0001193125-26-342512.md) | [31.5](/filings/0001193125-26-216790.md) | [36.5](/filings/0001193125-26-342512.md) |
| Total liabilities | $m | [11.7](/filings/0001437749-23-032036.md) | [22.7](/filings/0000950170-25-046758.md) | [48.4](/filings/0000950170-24-060427.md) | [44.9](/filings/0000950170-24-096148.md) | [62.7](/filings/0000950170-24-125399.md) | [50.4](/filings/0000728387-26-000004.md) | [44.7](/filings/0000950170-25-069314.md) | [45.0](/filings/0000950170-25-107619.md) | [52.6](/filings/0001193125-25-274328.md) | [59.9](/filings/0001193125-26-342512.md) | [63.3](/filings/0001193125-26-216790.md) | [68.2](/filings/0001193125-26-342512.md) |
| Long-term debt | $m | [1.7](/filings/0001437749-23-032036.md) | [1.7](/filings/0001437749-24-009696.md) | [1.7](/filings/0000950170-24-060427.md) | [1.7](/filings/0000950170-24-096148.md) | [1.7](/filings/0000950170-24-125399.md) | [1.7](/filings/0000950170-25-046758.md) | [1.7](/filings/0000950170-25-069314.md) | [1.7](/filings/0000950170-25-107619.md) | [1.6](/filings/0001193125-25-274328.md) | [1.6](/filings/0000728387-26-000004.md) | [1.6](/filings/0001193125-26-216790.md) | [1.6](/filings/0001193125-26-342512.md) |
| Shareholders' equity | $m | [98.8](/filings/0000950170-24-125399.md) | [75.2](/filings/0000728387-26-000004.md) | [230](/filings/0001193125-25-274328.md) | [341](/filings/0001193125-25-274328.md) | [328](/filings/0001193125-25-274328.md) | [291](/filings/0001193125-26-342512.md) | [285](/filings/0001193125-26-342512.md) | [266](/filings/0001193125-26-342512.md) | [242](/filings/0001193125-25-274328.md) | [207](/filings/0001193125-26-342512.md) | [347](/filings/0001193125-26-342512.md) | [324](/filings/0001193125-26-342512.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(10.1) d](/filings/0000950170-24-125399.md) | [(9.0) d](/filings/0000950170-25-046758.md) | [13.8](/filings/0000950170-25-069314.md) | [(8.9) d](/filings/0000950170-25-107619.md) | [3.4 d](/filings/0001193125-25-274328.md) | [(26.6) d](/filings/0000728387-26-000004.md) | [(21.6)](/filings/0001193125-26-216790.md) | [(20.0) d](/filings/0001193125-26-342512.md) | [(16.3) d](/filings/0001193125-25-274328.md) | [(24.7) d](/filings/0000728387-26-000004.md) | [(31.5)](/filings/0001193125-26-216790.md) | [(20.7) d](/filings/0001193125-26-342512.md) |
| Capital expenditure | $m | [0.2 d](/filings/0000950170-24-125399.md) | [0.1 d](/filings/0000950170-25-046758.md) | [9.1](/filings/0000950170-25-069314.md) | [1.0 d](/filings/0000950170-25-107619.md) | [29.7 d](/filings/0001193125-25-274328.md) | [14.6 d](/filings/0000728387-26-000004.md) | [4.7](/filings/0001193125-26-216790.md) | [1.0 d](/filings/0001193125-26-342512.md) | [2.0 d](/filings/0001193125-25-274328.md) | [5.1 d](/filings/0000728387-26-000004.md) | [6.9](/filings/0001193125-26-216790.md) | [14.2 d](/filings/0001193125-26-342512.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [229](/filings/0000950170-24-060427.md) | [28.0](/filings/0000950170-24-096148.md) | [28.1](/filings/0000950170-24-125399.md) | [49.5](/filings/0000950170-25-069314.md) | [66.6](/filings/0000950170-25-107619.md) | [70.6](/filings/0001193125-25-274328.md) | [72.4](/filings/0001193125-26-216790.md) | [74.2](/filings/0001193125-26-342512.md) | [74.3](/filings/0001193125-25-274328.md) | [104](/filings/0001193125-26-216790.md) | [121](/filings/0001193125-26-342512.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 114,151,663 at 2026-08-05, from the cover of the [10-Q filed 2026-08-10](/filings/0001193125-26-342512.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.